COVIDSeq™ – Unlocking the Power of Genomics for SARS-CoV-2 Surveillance  

Key Features and Benefits 

• Accurate: Detects 98 targets on SARS-CoV-2 RNA for highly accurate detection of mutations 
• Comprehensive: Reports consensus sequence when +90 amplicons are detected 
• Quality Controlled: Built-in quality control in every reaction 
• Flexible: Seamless end-to-end workflow; temperature specification allows use of different thermocyclers 

This amplicon-based next-generation sequencing (NGS) assay is designed to help clinical research labs identify novel strains of SARS-CoV-2. It includes 2019-nCoV primers to detect mutations and characterize RNA from the SARS-CoV-2 virus. 

Rapid, Low-Throughput SARS-CoV-2 Detection 

The Illumina COVIDSeq Assay accommodates a low number of samples. The workflow includes steps for viral RNA extraction, RNA-to-cDNA conversion, PCR, library preparation, sequencing, analysis, and report generation. 

Design and Quality Control 

The assay leverages a modified version of the publicly available ARTIC multiplex PCR protocol, with 98 amplicons designed to amplify SARS-CoV-2 virus-specific sequences, combined with proven Illumina sequencing technology. A 63°C annealing temperature at the PCR step improves variant analysis—providing important insight into the SARS-CoV-2 strain present in the sample. 

Upload consensus sequence information (FASTA file) into open software tools to assign lineage and annotate mutations. For added convenience, upload files to the NCBI and/or GISAID App directly through BaseSpace Sequencing Hub. 

Product

Illumina COVIDSeq ™ Assay (96 samples)

Certificate: ROU 

Supplier: Illumina 

For Mid and Low-throughput laboratories performing COVID-19 surveillance and identification of new variants